Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa.
J Nucl Med. 2011 Jun;52(6):880-5. doi: 10.2967/jnumed.110.083709. Epub 2011 May 13.
This prospective pilot study examined the relationship between the severity and extent of tuberculosis as assessed by (18)F-FDG PET at the time of diagnosis and response to treatment or treatment failure at 4 mo.
Twenty-four consecutive HIV patients with newly diagnosed tuberculosis were prospectively included in the study after providing written informed consent. Seventeen patients had pulmonary tuberculosis, and 7 patients had extrapulmonary tuberculosis. All patients underwent whole-body (18)F-FDG PET; none were receiving tuberculostatics at the time of the PET investigation. After undergoing (18)F-FDG PET, the patients were given tuberculosis treatment (the classic triad: isoniazid, rifampicin, and ethambutol) and reevaluated for treatment response: monthly assessment of sputum, smears, and cultures in patients who proved positive at the time of diagnosis, and clinical and radiologic (when relevant) assessment 4 mo after treatment instigation in all patients. Quantitative (18)F-FDG PET results (averaged (18)F-FDG maximum standardized uptake value [SUVmax] derived from early and delayed imaging), percentage change in SUVmax, and number of involved lymph node bastions were related to treatment response or failure.
Age, sex, viral load, CD4 status, duration of HIV treatment, SUVmax of lung and splenic lesions (early and delayed), and percentage change in SUVmax of lymph nodes were not significantly different between responders and nonresponders (P ≥ 0.3). In contrast, SUVmax of involved lymph node bastions (both early and delayed) and number of involved lymph node bastions were significantly higher in nonresponders than in responders (respective P values were 0.03, 0.04, and 0.002). Using a cutoff of 5 or more involved lymph node bastions, responders could be separated from nonresponders with a sensitivity, specificity, and positive and negative predictive value of, respectively, 88%, 81%, 70%, and 93%. Using a cutoff of 8.15 for early SUVmax of lymph node bastions and of 10 for late SUVmax of lymph node bastions, a comparable sensitivity of 88% came at the cost of a lower specificity: 73% and 67%, respectively.
In this pilot study, a cutoff of 5 or more involved lymph node bastions allowed for separation of tuberculostatic responsive and nonresponsive tuberculosis-infected HIV patients with a sensitivity of 88%, a specificity of 81%, and a negative predictive value of 93%. These findings warrant confirmation by additional studies on larger cohorts of patients.
本前瞻性研究旨在探讨初诊时(18)F-FDG PET 评估的结核严重程度和范围与 4 个月时的治疗反应或治疗失败之间的关系。
24 例新诊断为结核病的 HIV 连续患者在书面知情同意后前瞻性纳入研究。17 例患者为肺结核,7 例患者为肺外结核病。所有患者均接受全身(18)F-FDG PET 检查;进行 PET 检查时,无患者接受抗结核药物治疗。进行(18)F-FDG PET 后,患者给予抗结核治疗(经典三联:异烟肼、利福平、乙胺丁醇),并在治疗开始后 4 个月进行治疗反应评估:每月评估痰、涂片和培养结果(初诊时为阳性的患者),所有患者均进行临床和影像学(如有必要)评估。与治疗反应或失败相关的(18)F-FDG PET 结果(早期和延迟期平均(18)F-FDG 最大标准化摄取值[SUVmax])、SUVmax 变化百分比和受累淋巴结堡垒数量。
应答者和无应答者之间的年龄、性别、病毒载量、CD4 状态、HIV 治疗持续时间、肺部和脾脏病变的 SUVmax(早期和延迟)、淋巴结 SUVmax 变化百分比无显著差异(P≥0.3)。相反,无应答者受累淋巴结堡垒的 SUVmax(早期和延迟)和受累淋巴结堡垒数量均显著高于应答者(相应的 P 值分别为 0.03、0.04 和 0.002)。使用 5 个或更多受累淋巴结堡垒作为截断值,可将应答者与无应答者区分开,其敏感性、特异性、阳性和阴性预测值分别为 88%、81%、70%和 93%。使用早期淋巴结 SUVmax 的截断值为 8.15,晚期淋巴结 SUVmax 的截断值为 10,可获得 88%的相似敏感性,但特异性降低:分别为 73%和 67%。
在这项初步研究中,使用 5 个或更多受累淋巴结堡垒作为截断值,可以将结核分枝杆菌感染的 HIV 患者分为结核分枝杆菌药物治疗反应性和非反应性患者,其敏感性为 88%,特异性为 81%,阴性预测值为 93%。这些发现需要在更大的患者队列中进行更多研究来证实。